Netherlands· NL-86c4be655372
Tepkinly 48 mg oplossing voor injectie
A epcoritamab product containing epcoritamab, registered in Netherlands by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Epcoritamab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX27 (epcoritamab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Epcoritamab · ATC L01FX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of epcoritamab costs, country by country.
Normalised to the WHO defined daily dose (1.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Epcoritamab · price per daily dose (1.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$281.38
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EPCORITAMAB
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Netherlands (NL)
- ATC code
- L01FX27
- ATC class
- Epcoritamab
- Defined daily dose
- 1.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1759
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Epcoritamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceTEPKINLY 48 mg, solution injectableABBVIE DEUTSCHLAND (ALLEMAGNE)
- IrelandTepkinly 48 mg solution for injectionAbbVie Deutschland GmbH & Co. KG
- United StatesEPKINLYGenmab US, Inc.
- CanadaEPKINLYABBVIE CORPORATION
- SwitzerlandTepkinly 4 mg/0,8 ml, InjektionslösungAbbVie AG
- CzechiaTEPKINLYAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainTEPKINLY 4 MG/0,8 ML SOLUCION INYECTABLEAbbvie Deutschland Gmbh & Co. Kg
- FinlandTepkinlyAbbVie Deutschland GmbH&Co.KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tepkinly
- Iceland · Tepkinly
- Liechtenstein · Tepkinly
- Norway · Tepkinly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7d4cc6b4-168a-4ba9-abdd-0bd30b43e1c3 GET /v1/drugs/7d4cc6b4-168a-4ba9-abdd-0bd30b43e1c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Epcoritamab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130612",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"POLYSORBAAT 80 (E 433)",
"SORBITOL (E 420)",
"WATER VOOR INJECTIE"
],
"substances": [
"EPCORITAMAB"
],
"leaflet_url": null,
"authorised_at": "2023/09/22",
"procedure_number": "EMEA/H/C/005985",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1759",
"additional_monitoring": "Y"
}See everything about epcoritamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.